Ojobe Bukola, Okeowo Idris, Rathousky Jiri, Brabec Libor, Marikova Tereza, Mikyskova Eliska, Kofronova Jana, Vurm Radek, Smrckova Stepanka, Ashtiani Saeed Jamali, Friess Karel, Dzuman Zbynek, Kouba Vojtech, Bartacek Jan
Department of Water Technology and Environmental Engineering, University of Chemistry and Technology Prague, Technicka 5, 166 28 Prague, Czech Republic.
Center for Innovations in the Field of Nanomaterials and Nanotechnologies, J. Heyrovsky Institute of Physical Chemistry, Czech Academy of Sciences, Dolejskova 3, 182 23 Prague, Czech Republic.
ACS ES T Water. 2024 Nov 29;4(12):5587-5597. doi: 10.1021/acsestwater.4c00618. eCollection 2024 Dec 13.
Traditional wastewater treatment often fails to remove pharmaceuticals, necessitating advanced solutions, such as TiO photocatalysis, for post-treatment. However, conventionally applied powder TiO can be cumbersome to separate from treated water. To solve this issue, this study immobilized three TiO photocatalysts (Anatase 16, Anatase 5, and P25) into porous layers and evaluated their efficacy for the degradation of three pharmaceuticals (naproxen, NPX; sulfamethoxazole, SMX; metformin, MTF) in standard solutions and greywater pretreated in a membrane bioreactor (MBR). In standard solutions, photocatalysis tests revealed a high degradation efficacy (NPX 100%, SMX 76-95%, MTF 57-75%) and challenged the belief that OH is the predominant reactive oxygen species (ROS). The primary ROS were O for NPX and OH for SMX and MTF. The raw greywater (NPX, SMX, MTF - 0.5 mg·L) treatment in MBR removed only 17-22% of the pharmaceuticals, highlighting the need for post-treatment. Using this pretreated greywater, P25 layers excelled for NPX (78 ± 5%) and SMX (73 ± 4%) but were less effective for MTF (40 ± 16%) compared to Anatase 16 (60 ± 10%). Moreover, the effluent toxicity () was reduced, and the degradation products were identified. Overall, TiO layers are a high-potential method for removing pharmaceuticals from MBR-treated greywater.
传统的废水处理往往无法去除药物,因此需要采用先进的解决方案,如二氧化钛光催化,进行后处理。然而,传统应用的粉末状二氧化钛从处理后的水中分离可能会很麻烦。为了解决这个问题,本研究将三种二氧化钛光催化剂(锐钛矿型16、锐钛矿型5和P25)固定在多孔层中,并评估了它们在标准溶液和膜生物反应器(MBR)预处理的灰水中对三种药物(萘普生,NPX;磺胺甲恶唑,SMX;二甲双胍,MTF)的降解效果。在标准溶液中,光催化测试显示出高降解效率(NPX为100%,SMX为76 - 95%,MTF为57 - 75%),并对羟基自由基(OH)是主要活性氧物种(ROS)这一观点提出了挑战。对于NPX,主要的ROS是单线态氧(O),对于SMX和MTF则是羟基自由基(OH)。MBR中对原灰水(NPX、SMX、MTF - 0.5 mg·L)的处理仅去除了17 - 22%的药物,凸显了后处理的必要性。使用这种预处理后的灰水,与锐钛矿型16(60 ± 10%)相比,P25层对NPX(78 ± 5%)和SMX(73 ± 4%)的降解效果较好,但对MTF的效果较差(40 ± 16%)。此外,出水毒性降低,并鉴定出了降解产物。总体而言,二氧化钛层是从MBR处理后的灰水中去除药物的一种很有潜力的方法。